HCW BiologicsHCWB +1.82%39 Median PS Value is $0.00 as of Jun. 25, 2026. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $7.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 277 Biotechnology companies, HCW Biologics ranks worse than 361010.47% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. HCW Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.225. HCW Biologics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2026-06-25), HCW Biologics's share price is $1.12. HCW Biologics's Median PS Value is $0.00. Therefore, HCW Biologics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for HCW Biologics's Median PS Value or its related term are showing as below:
HCWB's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.63 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
HCW Biologics (NAS:HCWB) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
HCW Biologics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.12
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics Median PS Value Related Terms
HCW Biologics Median PS Value Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCWB vs MTVA, INTI, HOOK: Median PS Value Comparison
For the Biotechnology subindustry, HCW Biologics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
HCW Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.225.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a Median PS Value of $0.00 as of Jun. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #999999 out of 277 companies in the Biotechnology industry.
Is HCW Biologics' Median PS Value too high?
HCW Biologics' current Median PS Value is $0.00. Based on the distribution chart, HCW Biologics ranks #999999 out of 277 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Median PS Value compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #999999 out of 277 companies for Median PS Value. This places HCW Biologics in the lower half of its industry. The industry median Median PS Value is 0.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.12 — trading 84.6% below its estimated fair value. The current Median PS Value is $0.00. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Median PS Value is $0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $1.12 is trading 84.6% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Median PS Value: $0.00
GF Value™: $7.29 vs. price of $1.12 (84.6% below fair value)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
